MADRIGAL PHARMACEUTICALS, INC. MDGL
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
-1.18
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $958.4M | -$288.3M | — | -$190.0M | $602.7M |
| 2024 | $180.1M | -$465.9M | — | -$457.0M | $754.4M |
| 2023 | $0 | -$373.6M | — | -$325.7M | $405.3M |
| 2022 | $0 | -$295.4M | — | -$225.1M | $197.4M |
| 2021 | $0 | -$241.8M | — | -$184.1M | $196.1M |
| 2020 | $0 | -$202.2M | — | -$157.9M | $240.0M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -1.18 (distress)
- Working capital / assets 0.743
- Retained earnings / assets -1.66
- EBIT / assets -0.238
- Equity / liabilities 0.917
Source: SEC EDGAR filings · CIK 0001157601 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.